Verona Pharma
plc
("Verona Pharma" or the
"Company")
Notice of
Results
27 May 2016, Cardiff –
Verona Pharma plc (AIM: VRP), the drug development company focused
on first-in-class medicines to treat respiratory diseases, expects
to announce its preliminary results for the year ended 31 December 2015 on Friday 3 June 2016.
-Ends-
For further information please
contact:
| Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
| N+1 Singer |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer |
|
|
|
| FTI Consulting |
Tel: +44 (0)20 3727 1000 |
| Julia Phillips / Simon Conway |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a dual
phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has recently
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.